×
About 2,438 results

ALLMedicine™ Genital Warts Center

Research & Reviews  654 results

Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV r...
https://doi.org/10.1136/bmj-2022-070135
BMJ (Clinical Research Ed.); Kechagias KS, Kalliala I et. al.

Aug 4th, 2022 - To explore the efficacy of human papillomavirus (HPV) vaccination on the risk of HPV infection and recurrent diseases related to HPV infection in individuals undergoing local surgical treatment. Systematic review and meta-analysis DATA SOURCES: Pu...

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
https://clinicaltrials.gov/ct2/show/NCT05285826

Jul 28th, 2022 - This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age. It will enroll heterosexual men (HM) and men who have sex with men (MSM), will be strati...

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment
https://clinicaltrials.gov/ct2/show/NCT03682601

Jul 27th, 2022 - Topical Veregen (15% sinecatechins) is an FDA approved botanical drug derived from green tea and is approved to be used as multiple doses, three times a day to treat all visible external genital warts. Topical green tea ointment has been shown to ...

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and ...
https://doi.org/10.1080/21645515.2022.2078626
Human Vaccines & Immunotherapeutics; Maldonado I, Plata M et. al.

Jul 20th, 2022 - Among women aged 27-45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was a...

Immunogenicity of 9-valent HPV Vaccine
https://clinicaltrials.gov/ct2/show/NCT05439083

Jul 13th, 2022 - Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately 90% of cervical and ...

see more →

Guidelines  5 results

Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809.
https://doi.org/10.1097/AOG.0000000000004000
Obstetrics and Gynecology;

Aug 1st, 2020 - Human papillomavirus (HPV) causes significant morbidity and mortality in women and men. The HPV vaccine significantly reduces the incidence of anogenital cancer and genital warts in women and in men. Human papillomavirus vaccines are among the mos...

Committee Opinion No. 704 Summary: Human Papillomavirus Vaccination.
https://doi.org/10.1097/AOG.0000000000002111
Obstetrics and Gynecology;

May 26th, 2017 - Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and geni...

Committee Opinion No. 704: Human Papillomavirus Vaccination.
https://doi.org/10.1097/AOG.0000000000002052
Obstetrics and Gynecology;

Mar 28th, 2017 - Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and geni...

Sexually transmitted diseases treatment guidelines, 2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885289
MMWR. Recommendations and Reports : Morbidity and Mortali... Workowski KA, Bolan GA et. al.

Jun 5th, 2015 - These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30-M...

Committee opinion no. 588: human papillomavirus vaccination.
https://doi.org/10.1097/01.AOG.0000444458.00612.6b
Obstetrics and Gynecology;

Feb 21st, 2014 - The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that human papillomavirus (HPV) vaccination routinely be targeted to females and males aged 11 years or 12 years as part of the adolescen...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  84 results

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
https://clinicaltrials.gov/ct2/show/NCT05285826

Jul 28th, 2022 - This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age. It will enroll heterosexual men (HM) and men who have sex with men (MSM), will be strati...

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment
https://clinicaltrials.gov/ct2/show/NCT03682601

Jul 27th, 2022 - Topical Veregen (15% sinecatechins) is an FDA approved botanical drug derived from green tea and is approved to be used as multiple doses, three times a day to treat all visible external genital warts. Topical green tea ointment has been shown to ...

Immunogenicity of 9-valent HPV Vaccine
https://clinicaltrials.gov/ct2/show/NCT05439083

Jul 13th, 2022 - Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately 90% of cervical and ...

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
https://clinicaltrials.gov/ct2/show/NCT03180034

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. For each vaccine separately, to evaluate non-inferiority of one compared to two vaccination doses in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination. II....

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
https://clinicaltrials.gov/ct2/show/NCT05435209

Jun 28th, 2022 - Background: Genital Human Papilloma Virus (HPV) infections occur rapidly after sexual debut, and immunosuppressed individuals are at greater risk for incident and persistent infection. HPV vaccine contains virus-like particles (VLP), which are hig...

see more →

News  213 results

Physicians Shy From Notifying Patients' Partners of STIs
https://www.medscape.com/viewarticle/976068

Jun 23rd, 2022 - Less than 10% of family physicians in British Columbia, Canada, contact the partners of patients whom they have diagnosed with sexually transmitted infections (STIs), new data indicate. In an online survey of almost 150 family physicians throughou...

Labial growth
https://www.mdedge.com/familymedicine/article/252620/dermatology/labial-growth
MDedge Family Medicine;

Mar 10th, 2022 - White-to-pink friable plaques occurring acutely in the vulva is concerning for one form of secondary syphilis that affects mucous membranes: condyloma lata. Known as the great imitator for its variety of clinical presentations, syphilis is a sexua.

HPV Vaccination Rates Continue to Climb Among Young Adults in US
https://www.medscape.com/viewarticle/950043

Apr 27th, 2021 - Although vaccination rates against the human papillomavirus (HPV) remain low for young adults across the United States, the number of self-reported HPV vaccinations among women and men between the ages of 18 and 21 years has markedly increased sin...

FDA Approvals of HPV Vaccine and NGS Assay, Priority Review in Myeloma, and More
https://www.onclive.com/view/fda-approvals-of-hpv-vaccine-and-ngs-assay-priority-review-in-myeloma-and-more

Apr 2nd, 2021 - Today- FDA approvals of an HPV vaccine and a next-generation sequencing assay, a priority review designation in multiple myeloma, and an ODAC recommendation for a biosimilar. Welcome to OncLive News Network! I’m Gina Columbus. The FDA has...

2021 Update on gynecologic cancer
https://www.mdedge.com/obgyn/article/237049/gynecologic-cancer
Shayan Dioun, MD, Jason D. Wright, MD

Mar 10th, 2021 - Gynecologic malignancies continue to be a major cause of cancer-related mortality in women. In 2020, a number of developments changed practice in gynecologic oncology.

see more →

Patient Education  12 results see all →